Matuzumab

	WikiDoc Resources for Matuzumab
Articles
Most recent articles on Matuzumab Most cited articles on Matuzumab Review articles on Matuzumab Articles on Matuzumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Matuzumab Images of Matuzumab Photos of Matuzumab Podcasts & MP3s on Matuzumab Videos on Matuzumab
Evidence Based Medicine
Cochrane Collaboration on Matuzumab Bandolier on Matuzumab TRIP on Matuzumab
Clinical Trials
Ongoing Trials on Matuzumab at Clinical Trials.gov Trial results on Matuzumab Clinical Trials on Matuzumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Matuzumab NICE Guidance on Matuzumab NHS PRODIGY Guidance FDA on Matuzumab CDC on Matuzumab
Books
Books on Matuzumab
News
Matuzumab in the news Be alerted to news on Matuzumab News trends on Matuzumab
Commentary
Blogs on Matuzumab
Definitions
Definitions of Matuzumab
Patient Resources / Community
Patient resources on Matuzumab Discussion groups on Matuzumab Patient Handouts on Matuzumab Directions to Hospitals Treating Matuzumab Risk calculators and risk factors for Matuzumab
Healthcare Provider Resources
Symptoms of Matuzumab Causes & Risk Factors for Matuzumab Diagnostic studies for Matuzumab Treatment of Matuzumab
Continuing Medical Education (CME)
CME Programs on Matuzumab
International
Matuzumab en Espanol Matuzumab en Francais
Business
Matuzumab in the Marketplace Patents on Matuzumab
Experimental / Informatics
List of terms related to Matuzumab

Template:Drugbox-mab

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to EGFR (epithelial growth factor receptor) with high affinity.

Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it is currently undergoing phase II clinical trials for the treatment of colorectal, lung and stomach cancer. On August 29, 2007, Merck Serono announced that the preliminary results of the colorectal cancer study were less than promising, and that further trials for treating this type of cancer may be abandoned. The results of the lung and stomach cancer studies are expected in 2008.^[1]